EU REACH
This article was originally published in The Rose Sheet
Executive Summary
European Commission "expect[s] decisive progress to be achieved before the end of the year" on the implementation of the Registration, Evaluation and Authorization of Chemicals program, with the first European Parliament reading of the proposal anticipated in November, VP Gunter Verheugen says in recent letter to Greenpeace. Letter responds to concerns by the environmental group over the ability of the chemicals program to protect consumers. Verheugen notes that final version of REACH must include "pragmatic solutions" to several feasibility issues that have arisen since the proposal was introduced in 2003...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.